Comparative Pharmacology
Head-to-head clinical analysis: MOXIFLOXACIN HYDROCHLORIDE versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXIFLOXACIN HYDROCHLORIDE versus ZAGAM.
MOXIFLOXACIN HYDROCHLORIDE vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg orally or intravenously once daily for most indications; duration varies by indication.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-14 hours in healthy adults, allowing once-daily dosing. This is extended in severe renal impairment (creatinine clearance <30 mL/min) and in the elderly.
10-12 hours; prolonged in renal impairment
Approximately 20% of a dose is excreted unchanged in urine, with about 25% recovered as a glucuronide conjugate (M1) and a sulfate conjugate (M2). Biliary/fecal excretion accounts for about 55% of the dose, with a portion undergoing enterohepatic recirculation.
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic